Cyclopharm Ltd
ASX:CYC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Cyclopharm Ltd
ASX:CYC
|
AU |
|
D
|
DSM-Firmenich AG
AEX:DSFIR
|
CH |
|
B
|
Bergman & Beving AB
STO:BERG B
|
SE |
Cyclopharm Ltd
Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.
Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.
Record Revenue: Cyclopharm reported record half-year revenue of $15.42 million, up 26% year-on-year.
US Growth: US Technegas revenue doubled to $1.24 million, with installations rising from 17 to 35 during the half.
Third-Party Distribution: Revenue from third-party products grew 58% to $7.76 million, highlighting strong growth in this segment.
Margins & Investment: Gross margin increased 20% to $8.26 million. Operating expenses rose by a modest 12%, lower than revenue growth, reflecting deliberate investment in US expansion.
Cash Position: Cyclopharm ended the half with $12.4 million in cash, with an additional $6.2 million expected in H2 from an asset sale.
Guidance Affirmed: Management reaffirmed its US growth strategy and maintained financial guidance, citing a robust pipeline and expanding sales team.
Rest of World Dip: Technegas revenue outside the US fell temporarily due to a distributor in France reducing inventory, not underlying demand.
